HK Stock Market Move | SINO BIOPHARM(01177) rises more than 4%, management is optimistic about the prospects of VIIa being included in insurance coverage. The drug is developed by its subsidiary, Zhongda Tianqing.

SINO BIOPHARM (01177) rose more than 4%, rising to 3.5% as of the time of publication, at 7.09 Hong Kong dollars, with a turnover of 431 million Hong Kong dollars. UBS released a research report stating that the management of SINO BIOPHARM mentioned that more time is needed to determine the development direction of the company's authorization (BD) business this year. It is expected that the data results to be announced this year will include the Phase I clinical data of TQB3702 in blood cancer, the Phase II clinical data of TQA3334, and the Phase III clinical data of lanifibranor for the treatment of metabolism-related fatty liver disease. As for the results of the 2025 national medical insurance drug catalog negotiation, the management is optimistic about the prospect of VIIa's selection, as only 3 companies were selected for inclusion. At the same time, penpulimab has successfully entered the medical insurance catalog for the first time; anlotinib has been approved for expansion to the first-line treatment of soft tissue sarcoma without any price reductions, while Yilishu has benefited from the expansion of reimbursement scope. Public information shows that SINO BIOPHARM's VIIa variety is the injection recombinant human coagulation factor VIIa N01 developed by its subsidiary Zhen Dai Tian Qing (commercial name: Anqixin), which was approved for listing by the NMPA on July 3, 2025. As the first domestic recombinant human coagulation factor VIIa biological product in China, it has broken the long-term monopoly of imported products, improved the accessibility of medication for patients with inhibitors positive hemophilia, and lowered the treatment costs for patients.